FOR IMMEDIATE RELEASE – December 14, 2020
BOSTON, MA – NSBE Boston is delighted to announce its first ever one-year Visionary Level corporate partnership with Repare Therapeutics (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by their proprietary synthetic lethality approach to the development of novel therapeutics.
Repare is committed to increasing career and professional development opportunities for minorities in STEM, through dedicated mentorship and training programs.
“We know that building a diverse and inclusive staff fosters creativity and collaboration which produces more innovative solutions for patients. Our partnership with NSBE supports our continued commitment to growing a diverse community of scientists and professionals in the Boston area through career mentorship and training programs,” said Lloyd M. Segal, President and CEO at Repare Therapeutics
As a partner, Repare will provide support to NSBE Boston at the Visionary sponsorship level. Through this sponsorship, the firm will collaborate on 2021 STEM initiatives with professional and career development programs aimed at both professionals and students, mentoring and community engagement programs.
“NSBE Boston is glad to welcome Repare Therapeutics and we hope this partnership strengthens all efforts to create career opportunities for our members and increase interest in STEM for students,” – Marilyn Louis, NSBE Boston Vice President Chair.
To kick off the partnership, Repare will collaborate on hosting an upcoming Youth STEM Day this winter.
Repare Therapeutics (Nasdaq: RPTX) is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500 a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs.